© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Shannon Westin, MD, analyzes the diagnosis and treatment of a 68-year-old woman with recurrent ovarian cancer.
March 26th 2021
Shannon Westin, MD, introduces the case patient and highlights the diagnosis and treatment path to combat stage IV ovarian cancer.
Shannon Westin, MD, discusses the prognosis of the case patient and the general prognosis and treatment options for ovarian cancer patients overall.
Shannon Westin, MD, analyzes the role of molecular testing in newly diagnosed ovarian cancer.
Systemic frontline therapy options are explored through the lens of treating ovarian cancer.
Shannon Westin, MD, discusses niraparib and its relation to the design, efficacy, and practical implications of the PRIMA trial.
The utilization and effectiveness of using PARP inhibitors in treating ovarian cancer is considered.
Shannon Westin, MD, reviews essential treatment considerations for physicians when subscribing niraparib.
The future of ovarian cancer treatment is discussed through a summary of current treatment options, future directions, and a review the unmet needs facing patients and physicians today.